Suppr超能文献

在慢性阻塞性肺疾病(COPD)中,与福莫特罗加布地奈德联合使用时茶碱的疗效、耐受性和安全性研究。

The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.

作者信息

Jindal Apar, Viswambhar V, V Arun Babu

机构信息

Associate Professor, Department of Respiratory Medicine, Chettinad Hospital & Research Institute , Chennai, India .

Post Graduate Student, Department of Respiratory Medicine, Chettinad Hospital & Research Institute , Chennai, India .

出版信息

J Clin Diagn Res. 2015 Feb;9(2):OC10-3. doi: 10.7860/JCDR/2015/10803.5527. Epub 2015 Feb 1.

Abstract

BACKGROUND

Chronic obstructive pulmonary disease (COPD) is a common disease causing significant socioeconomic burden. COPD patients, commonly smokers develop resistance to inhaled steroids attributed to deficiency of histone deacetylase 2 (HDAC2). The study of relationship between systemic inflammation and functional performance demonstrated that increased CRP level is inversely related to six minute walk distance (SMWD) and Forced Expired Volume in one second (FEV1). Theophylline restores HDAC2 activity thereby unlocking steroid resistance and potentiating inhaled corticosteroids (ICS) action culminating in reduced airway inflammation and mortality.

AIM

To study the effects of addition of Theophylline to the combination of Formoterol plus Budesonide on various objective and subjective parameters in moderate to severe COPD patients and to assess the safety profile of the combination. Setting and Study design: A single blinded, prospective, randomized, placebo controlled study at a tertiary care hospital in Jaipur, India.

MATERIALS AND METHODS

Fifty eight patients diagnosed with moderate to severe COPD were randomized into two groups. Group A patients received Formoterol 24μg plus budesonide 800μg daily in divided doses along with Theophylline while group B patients received Formoterol 24μg plus budesonide 800μg daily in divided doses along with placebo tablets. Both groups were followed up on 15th, 30th &60th day. During every visit all patients were assessed subjectively (symptom scoring) and objectively (spirometry, CRP, SMWT) and adverse effects if any were recorded. The obtained data subject to statistical analysis using"Graph pad Instat3" software.

RESULTS

Statistically significant improvement with a decline in total symptom score (p < 0.0001) was found with respect to "Night symptoms"&"SOB on rising" in group A. Theophylline group showed significant improvement in SMWD and FEV1.Mean fall in CRP was greater in Group A (not statistically significant). No side effects requiring withdrawal of drug were noted with Theophylline.

CONCLUSION

Addition of Theophylline to Formoterol plus Budesonide reduces dyspnea, improves exercise performance and pulmonary functions in moderate to severe COPD. Further studies are required to explore if reduced dosage would have equal efficacy with better safety and tolerability profile.

摘要

背景

慢性阻塞性肺疾病(COPD)是一种造成重大社会经济负担的常见疾病。COPD患者(通常为吸烟者)会因组蛋白去乙酰化酶2(HDAC2)缺乏而对吸入性类固醇产生耐药性。全身性炎症与功能表现之间关系的研究表明,C反应蛋白(CRP)水平升高与6分钟步行距离(SMWD)和一秒用力呼气量(FEV1)呈负相关。茶碱可恢复HDAC2活性,从而消除类固醇耐药性并增强吸入性糖皮质激素(ICS)的作用,最终减轻气道炎症并降低死亡率。

目的

研究在福莫特罗加布地奈德的联合用药中添加茶碱对中度至重度COPD患者各种客观和主观参数的影响,并评估该联合用药的安全性。设置与研究设计:在印度斋浦尔的一家三级护理医院进行的单盲、前瞻性、随机、安慰剂对照研究。

材料与方法

58例诊断为中度至重度COPD的患者被随机分为两组。A组患者每日分剂量接受24μg福莫特罗加800μg布地奈德以及茶碱治疗,而B组患者每日分剂量接受24μg福莫特罗加800μg布地奈德以及安慰剂片治疗。两组患者均在第15天、第30天和第60天进行随访。每次随访时,对所有患者进行主观评估(症状评分)和客观评估(肺功能测定、CRP、SMWT),并记录任何不良反应。使用“Graph pad Instat3”软件对获得的数据进行统计分析。

结果

A组在“夜间症状”和“起身时气短”方面,总症状评分有统计学意义的改善(p < 0.0001)。茶碱组的SMWD和FEV1有显著改善。A组CRP的平均下降幅度更大(无统计学意义)。使用茶碱未发现需要停药的副作用。

结论

在福莫特罗加布地奈德中添加茶碱可减轻中度至重度COPD患者的呼吸困难,改善运动表现和肺功能。需要进一步研究以探索降低剂量是否具有同等疗效以及更好的安全性和耐受性。

相似文献

1
The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.
J Clin Diagn Res. 2015 Feb;9(2):OC10-3. doi: 10.7860/JCDR/2015/10803.5527. Epub 2015 Feb 1.
2
Formoterol: a review of its use in chronic obstructive pulmonary disease.
Am J Respir Med. 2002;1(4):285-300. doi: 10.1007/BF03256622.
5
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005.
6
Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev. 2004(3):CD003794. doi: 10.1002/14651858.CD003794.pub2.
8
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Eur Respir J. 2003 Jan;21(1):74-81. doi: 10.1183/09031936.03.00031402.
9
Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
Int J Chron Obstruct Pulmon Dis. 2016 Feb 25;11:381-90. doi: 10.2147/COPD.S93303. eCollection 2016.

引用本文的文献

2
Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis.
PLoS One. 2021 May 24;16(5):e0251348. doi: 10.1371/journal.pone.0251348. eCollection 2021.
7
Emerging pharmaceutical therapies for COPD.
Int J Chron Obstruct Pulmon Dis. 2017 Jul 21;12:2141-2156. doi: 10.2147/COPD.S121416. eCollection 2017.
8
C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis.
Eur Respir Rev. 2017 Jan 31;26(143). doi: 10.1183/16000617.0070-2016. Print 2017 Jan.
9
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.
Ther Adv Chronic Dis. 2016 Jan;7(1):34-51. doi: 10.1177/2040622315609251.

本文引用的文献

2
Theophylline for COPD.
Thorax. 2006 Sep;61(9):742-4. doi: 10.1136/thx.2006.061002.
3
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.
Eur Respir J. 2006 May;27(5):902-7. doi: 10.1183/09031936.06.00109605. Epub 2006 Feb 2.
5
C-reactive protein in patients with COPD, control smokers and non-smokers.
Thorax. 2006 Jan;61(1):23-8. doi: 10.1136/thx.2005.042200. Epub 2005 Sep 2.
6
Raised CRP levels mark metabolic and functional impairment in advanced COPD.
Thorax. 2006 Jan;61(1):17-22. doi: 10.1136/thx.2005.041996. Epub 2005 Jul 29.
7
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.
J Exp Med. 2004 Sep 6;200(5):689-95. doi: 10.1084/jem.20040416. Epub 2004 Aug 30.
8
Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2004 Oct 1;170(7):760-5. doi: 10.1164/rccm.200404-543OC. Epub 2004 Jun 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验